Tetrabenazine: The First Approved Drug for the Treatment of Chorea in US Patients with Huntington Disease

OpenBU

Show simple item record

dc.contributor.author Frank, Samuel en_US
dc.date.accessioned 2012-01-11T21:07:27Z
dc.date.available 2012-01-11T21:07:27Z
dc.date.issued 2010-10-05 en_US
dc.identifier.citation Frank, Samuel. "Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease" Neuropsychiatric Disease and Treatment 6: 657-665. (2010) en_US
dc.identifier.issn 1178-2021 en_US
dc.identifier.uri http://hdl.handle.net/2144/3180
dc.description.abstract Huntington disease (HD) is a dominantly inherited progressive neurological disease characterized by chorea, an involuntary brief movement that tends to flow between body regions. HD is typically diagnosed based on clinical findings in the setting of a family history and may be confirmed with genetic testing. Predictive testing is available to those at risk, but only experienced clinicians should perform the counseling and testing. Multiple areas of the brain degenerate mainly involving the neurotransmitters dopamine, glutamate, and γ-aminobutyric acid. Although pharmacotherapies theoretically target these neurotransmitters, few well-conducted trials for symptomatic or neuroprotective interventions yielded positive results. Tetrabenazine (TBZ) is a dopamine-depleting agent that may be one of the more effective agents for reducing chorea, although it has a risk of potentially serious adverse effects. Some newer antipsychotic agents, such as olanzapine and aripiprazole, may have adequate efficacy with a more favorable adverse-effect profile than older antipsychotic agents for treating chorea and psychosis. This review will address the epidemiology and diagnosis of HD as background for understanding potential pharmacological treatment options. Because TBZ is the only US Food and Drug Administration-approved medication in the United States for HD, the focus of this review will be on its pharmacology, efficacy, safety, and practical uses. There are no current treatments to change the course of HD, but education and symptomatic therapies can be effective tools for clinicians to use with patients and families affected by HD. en_US
dc.language.iso en en_US
dc.publisher Dove Medical Press en_US
dc.rights Copyright 2010 Frank, publisher and licensee Dove Medical Press Ltd. en_US
dc.subject Dopamine-depleting agent en_US
dc.subject Neuroleptics en_US
dc.subject Tetrabenazine en_US
dc.title Tetrabenazine: The First Approved Drug for the Treatment of Chorea in US Patients with Huntington Disease en_US
dc.type article en_US
dc.identifier.doi 10.2147/NDT.S6430 en_US
dc.identifier.pubmedid 20957126 en_US
dc.identifier.pmcid 2951749 en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search OpenBU


Advanced Search

Browse

Deposit Materials